Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

Trial Details

NCT ID
NCT03571321
Phase
PHASE1
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ruxolitinib
  • Cyclophosphamide
  • Cytarabine
  • Mercaptopurine
  • Vincristine
  • Pegaspargase
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must hav…
  • "Ph-like" signature, as determined by low density micro-array (LDA) card
  • Jak-targetable genetic signature as defined by any of the following:
  • Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →